Despite Global Restructuring Plan, It’s Full Steam Ahead In China For Merck
This article was originally published in PharmAsia News
Days after announcing a global restructuring plan, Merck CEO Ken Frazier visits Beijing to pledge $6 million toward the second phase of C-MAP, a public-private partnership with the Chinese government on HIV/AIDS. Frazier’s trip underscores the continuing importance of China to Merck despite a company-wide plan to cut 8,500 positions and reduce operating costs by $2.5 billion by 2015.
You may also be interested in...
Merck will cut 8,500 positions and reduce operating costs by $2.5 billion by 2015 to jumpstart growth in the midst of slowing sales and several late-stage pipeline setbacks. A key initiative is to recharge R&D by reinvesting in key projects and increasing business development activities.
BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.
In a key step to prop up traditional Chinese medicines, Beijing has proposed a law that could potentially punish any vocal doubters. The move signals a familiar pattern as China resorts to using old approaches when facing a flurry of new challenges.